Related Experiment Video
Updated: May 20, 2025
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Sex Differences in Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy
Jia Yi Tan1, Yong Hao Yeo2, Hermon Wong Kha Kin3
1Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.
Background:
Chimeric Antigen Receptor (CAR) T-cell therapy has arisen as a revolutionary treatment for hematologic malignancies. Our study aimed to evaluate how sex differences affect outcomes and complications following CAR T-cell therapy.
Methods:
Utilizing the Nationwide Readmissions Database (2018-2020), we identified patients and divided them into male and female groups. Hospital outcomes and complications were compared among these two groups after propensity score matching to match groups based on comorbidities, producing two comparable cohorts.
Results:
We analyzed 2928 patients (1832 males, 62.6%, mean age 60.3 ± 13.7 years; 1096 females, 37.4%, mean age 59.1 ± 13.8 years). After propensity score matching (1:1ratio), 1092 males and females were compared. There were no significant sex differences in early mortality (adjusted odd ratios (aOR): 1.04 [95% CI 0.69-1.57]), 30-day readmissions (aOR: 1.05 [95% CI 0.86-1.30]), or nonhome discharge (aOR: 0.89 [95% CI 0.60-1.31]). Females had higher odds of leukopenia (aOR: 1.26 [95% CI 1.06-1.50]) but lower odds of acute kidney injury (aOR: 0.68 [95% CI 0.52-0.88]).
Conclusions:
No sex differences were found in hospital outcomes, including early mortality, 30-day readmission, and nonhome discharge after CAR T-cell therapy.
More Related Videos
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025